⚙
AI-generated summary
by claude@2026-07, 2026-07-17
ⓘ
Wnt3a treatment increased proliferation, migration, collagen gel contraction, and αSMA expression in human endometrial stromal cells, partly via β-catenin.
⚙
AI-generated deep summary
by claude@2026-07, 2026-07-17
· read from full text
ⓘ
The paper investigated how activating Wnt/β-catenin signaling affects profibrotic and fibrogenic responses in primary endometrial stromal cells, using Wnt3a (150 ng/mL) or β-catenin siRNA and comparing effects to vehicle and TGF-β1, with measurements including Axin2 as a Wnt target and profibrotic markers such as αSMA, Col-I, CTGF, and FN. Wnt3a increased Axin2 mRNA over time and, at 24 hours, β-catenin knockdown reduced the Wnt3a-induced profibrotic marker expression, alongside assessments of proliferation, migration, and collagen gel contraction after treatment. A key limitation is that experiments were conducted in stromal cells derived from patients without endometriosis (n values are small across assays), so findings may not directly reflect endometriosis-associated tissue contexts. Relevance to endometriosis: the figure and study are explicitly framed as part of “Wnt/β-Catenin Signaling…in…fibrosis in endometriosis,” making it indirectly related to endometriosis via its mechanistic focus on profibrotic pathways, though the experiments used cells from patients without endometriosis.
Abstract
A: Axin2 mRNA expression in endometrial stromal cells treated with vehicle or Wnt3a (150 ng/mL) for 0, 4, 8, 12, 24, 48, or 72 h (n=5). *: p<.05 versus vehicle-treated controls.\nB: Effects of β-catenin siRNA on the mRNA expression of αSMA, Col-I, CTGF, and FN in endometrial stromal cells treated with vehicle, Wnt3a (150 ng/mL), or TGF-β1 (5 ng/mL) for 24 h (n=10). C: control siRNA-transfected cells; ß: ß-catenin siRNA-transfected cells.\n*: p<.05 versus control (C) cells without stimulation.\n**: p<.05 versus control (C) cells with Wnt3a stimulation.\n***: p<.05 versus control (C) cells with TGF-β1 stimulation.\nC: Cell proliferation of endometrial stromal cells treated with vehicle or Wnt3a (150 ng/mL) for 72 h (n=5). *: p<.05 versus vehicle-treated controls.\nD: Cell migration of endometrial stromal cells treated with vehicle or Wnt3a (150 ng/mL) for 72 h (n=5). *: p<.05 versus vehicle-treated controls.\nE: Collagen gel contraction of stromal cells treated for 24 h with vehicle or Wnt3a (150 ng/mL) (n=5), and representative photomicrographs of contracted gels taken at 24 h in stromal cells treated with vehicle or Wnt3a (150 ng/mL). *:p<.05 versus vehicle-treated controls.\nF: Percentage of αSMA-positive cells treated for 24 h with vehicle, Wnt3a (150 ng/mL), or TGF-β1 (5 ng/mL) (n=5). *:p<.05 versus vehicle-treated controls.\nG: Representative photomicrographs of endometrial stromal cells from the same patient after treatment with vehicle, Wnt3a (150 ng/mL), or TGF-β1 (5 ng/mL) for 24 h and stained for f-actin (red) or αSMA (green) and nuclei (blue). Scale bar, 100 μm.\nNumerical values are presented as the mean + SEM. Expression levels of axin2, αSMA, Col-I, CTGF, and FN mRNAs are given relative to the expression of the reference gene, GAPDH.
Full text
2,012 characters
· extracted from
oa-doi-fallback
· click to expand
Involvement of the Wnt/β-Catenin Signaling Pathway in the Cellular and Molecular Mechanisms of Fibrosis in Endometriosis
Figure 4
Effects of Wnt3a treatment on profibrotic responses in endometrial stromal cells of patients without endometriosis.
A: Axin2 mRNA expression in endometrial stromal cells treated with vehicle or Wnt3a (150 ng/mL) for 0, 4, 8, 12, 24, 48, or 72 h (n=5). *: p<.05 versus vehicle-treated controls.
B: Effects of β-catenin siRNA on the mRNA expression of αSMA, Col-I, CTGF, and FN in endometrial stromal cells treated with vehicle, Wnt3a (150 ng/mL), or TGF-β1 (5 ng/mL) for 24 h (n=10). C: control siRNA-transfected cells; ß: ß-catenin siRNA-transfected cells.
*: p<.05 versus control (C) cells without stimulation.
**: p<.05 versus control (C) cells with Wnt3a stimulation.
***: p<.05 versus control (C) cells with TGF-β1 stimulation.
C: Cell proliferation of endometrial stromal cells treated with vehicle or Wnt3a (150 ng/mL) for 72 h (n=5). *: p<.05 versus vehicle-treated controls.
D: Cell migration of endometrial stromal cells treated with vehicle or Wnt3a (150 ng/mL) for 72 h (n=5). *: p<.05 versus vehicle-treated controls.
E: Collagen gel contraction of stromal cells treated for 24 h with vehicle or Wnt3a (150 ng/mL) (n=5), and representative photomicrographs of contracted gels taken at 24 h in stromal cells treated with vehicle or Wnt3a (150 ng/mL). *:p<.05 versus vehicle-treated controls.
F: Percentage of αSMA-positive cells treated for 24 h with vehicle, Wnt3a (150 ng/mL), or TGF-β1 (5 ng/mL) (n=5). *:p<.05 versus vehicle-treated controls.
G: Representative photomicrographs of endometrial stromal cells from the same patient after treatment with vehicle, Wnt3a (150 ng/mL), or TGF-β1 (5 ng/mL) for 24 h and stained for f-actin (red) or αSMA (green) and nuclei (blue). Scale bar, 100 μm.
Numerical values are presented as the mean + SEM. Expression levels of axin2, αSMA, Col-I, CTGF, and FN mRNAs are given relative to the expression of the reference gene, GAPDH.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.